Discovery of SHR1127, an orally bioavailable, highly potent and selective KRAS G12D inhibitor

被引：0
|
作者：
Li, Xin
Shen, Feng
Zhang, Limin
Wang, Wei
Kong, Luyao
Bao, Yong
Mao, Yuchang
Wang, Zaiyong
Lin, Sophie
Zhang, Zhe
Feng, Jun
Hu, Min
He, Feng
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-7279
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7279
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Preclinical characterization of LY3962673, an orally bioavailable, highly potent, and selective KRAS G12D inhibitor
    Iyer, Chandrasekar
    Li, Binghui
    Stewart, Trent R.
    Wang, Tao
    Capen, Andrew
    Cavitt, Rachel
    Anderson, Bryan D.
    Bocchinfuso, Wayne
    Zhao, Gaiying
    Rodriguez, Michael J.
    Carballares, Santiago
    Cooke, Andrew
    Bondi, Robert
    Burns, Lee
    Kelamangalath, Lakshmi
    Wallace, Ross
    Kolakowski, Gabrielle
    Henry, James R.
    Si, Chong
    [J]. MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [2] INCB161734: A novel, potent, and orally bioavailable KRAS G12D selective inhibitor demonstrates antitumor activity in KRAS G12D mutant tumors
    Farren, Matthew R.
    Roman, Valerie
    Gallion, Alexandra
    Allali-Hassani, Abdellah
    Sokolsky, Alexander
    Kong, Weixi
    Smith, Amanda
    Wang, Hui
    Correa, Gina
    Deller, Marc
    Epling, Leslie B.
    Procak, Jessica
    Zhang, Guofeng
    Pecko, Katherine
    Kennedy, Keith
    Boer, Jason
    Kurzeja-Lipinski, Kerri
    Covington, Maryanne
    Chen, Kwang-Jong
    Wallower, Renee
    Rocha, Jennifer
    Pan, Rina
    Perry, Anthony
    Yuska, Brad
    Wang, Xiaozhao
    Macarron, Ricardo
    Kim, Sunkyu
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [3] Discovery and characterization of QTX3034, a potent, selective, and orally bioavailable allosteric KRAS inhibitor
    Zhang, Yang W.
    Rominger, Dave
    Vo, Elizabeth Donohue
    Silva, Jillian M.
    Zhang, Yang J.
    Lee, Greg
    Micozzi, John
    Reid, Ben
    McDonough, Brooke
    Hospital, Audrey
    Luengo, Juan I.
    Pitt, Cameron
    Lin, Hong
    [J]. CANCER RESEARCH, 2023, 83 (08)
  • [4] Discovery and characterization of QTX3544, a potent, selective, and orally bioavailable allosteric G12V preferring multi KRAS inhibitor
    Zhang, Yang W.
    Vo, Elizabeth Donohue
    Gan, Pei
    Rominger, Dave
    Silva, Jillian M.
    Zhang, Yang J.
    Pan, Christopher
    Lee, Greg
    Micozzi, John M.
    Ben Reid
    McDonough, Brooke
    Sinha, Arghyotri
    Hospital, Audrey
    Krauth, Doug
    Luengo, Juan I.
    Kramer, Mike
    Pitt, Cameron
    Lin, Hong
    [J]. CANCER RESEARCH, 2024, 84 (07)
  • [5] LY3962673, an oral, highly potent, mutant-selective, and non-covalent KRAS G12D inhibitor demonstrates robust anti-tumor activity in KRAS G12D models
    Gong, Xueqian
    Gao, Hong
    Bender, Mark H.
    Ming, Wenyu
    Zhang, Youyan
    Stewart, Trent R.
    Yu, Chun Ping
    Xu, Wei Guo
    You, Aurthur Xintian
    Bian, Wen Ting
    Li, Binghui
    Wang, Tao
    Bian, Huimin
    Tandon, Manuj
    Capen, Andrew
    Cavitt, Rachel N.
    Anderson, Bryan D.
    Bocchinfuso, Wayne
    Klippel, Anke
    Iyer, Chandrasekar
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [6] Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor
    Johnson, Douglas S.
    Stiff, Cory
    Lazerwith, Scott E.
    Kesten, Suzanne R.
    Fay, Lorraine K.
    Morris, Mark
    Beidler, David
    Liimatta, Marya B.
    Smith, Sarah E.
    Dudley, David T.
    Sadagopan, Nalini
    Bhattachar, Shobha N.
    Kesten, Stephen J.
    Nomanbhoy, Tyzoon K.
    Cravatt, Benjamin F.
    Ahn, Kay
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (02): : 91 - 96
  • [7] Structure-Based Design and Synthesis of Potent and Selective KRAS G12D Inhibitors
    Cheng, Hengmiao
    Li, Puhui
    Chen, Ping
    Irimia, Adriana
    Bae, Jae Hyun
    Brooun, Alexei
    Fagan, Patrick
    Lam, Richard
    Lin, Bingzhen
    Zhang, Jingchuan
    Zhan, Xuejun
    Wu, Xu
    Xie, Nan
    Chiang, Gary
    Shoemaker, Robert
    Vernier, Jean-Michel
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2023, 14 (10): : 1351 - 1357
  • [8] Discovery of a highly selective, orally bioavailable, brainpenetrant LRRK2 Inhibitor
    Gasser, Thomas
    Oprea, Tudor
    Kahle, Philipp
    Dahl, Bernadette
    Riebenbauer, Benjamin
    Bertoli, Federico
    Izzi, Francesca
    Deleidi, Michela
    Mochalov, Stepan
    Bulanova, Elena
    Ryakhovskiy, Alexey
    Kysil, Volodymyr
    Dukes, Iain
    Savchuk, Nikolay
    Karapetian, Ruben
    Guaitoli, Giambattista
    Gloeckner, Christian-Johannes
    Pushechnikov, Alexei
    [J]. MOVEMENT DISORDERS, 2023, 38 : S7 - S7
  • [9] Discovery and characterization of QTX3046, a potent, selective, and orally bioavailable non-covalent KRASG12D inhibitor
    Vo, Elizabeth Donohue
    Zhang, Yang W.
    Rominger, Dave
    Silva, Jillian M.
    Zhang, Yang J.
    Lee, Greg
    Micozzi, John
    Reid, Ben
    McDonough, Brooke
    Hospital, Audrey
    Luengo, Juan I.
    Lin, Hong
    Pitt, Cameron
    [J]. CANCER RESEARCH, 2023, 83 (08)
  • [10] Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor
    Gillman, Kevin W.
    Starrett, John E., Jr.
    Parker, Michael F.
    Xie, Kai
    Bronson, Joanne J.
    Marcin, Lawrence R.
    McElhone, Kate E.
    Bergstrom, Carl P.
    Mate, Robert A.
    Williams, Richard
    Meredith, Jere E., Jr.
    Burton, Catherine R.
    Barten, Donna M.
    Toyn, Jeremy H.
    Roberts, Susan B.
    Lentz, Kimberley A.
    Houston, John G.
    Zaczek, Robert
    Albright, Charles F.
    Decicco, Carl P.
    Macor, John E.
    Olson, Richard E.
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (03): : 120 - 124
12345